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5Summary 
With nearly 300 new psychoactive substances (NPS) reported to the EU’s early warning 
system in the 2013-2015 period, the evolution of the European market for NPS has 
accelerated to a speed that the public authorities’ established response — drug control 
laws — has struggled to match. Varying legal responses have been introduced in different 
countries, whether: by using existing laws that focused on consumer or health protection 
or medicinal products; by modifying drug laws to introduce group definitions of substances 
under control; or by developing innovative new legislation. Use of medicinal product laws 
— which are based on an EU directive — was challenged in the Court of Justice of the 
European Union (CJEU), which ruled in 2014 that substances are not medicinal products if 
they do not have beneficial effects on human health. As a result, Eurojust and the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) were called upon to consider 
challenges for judicial cooperation and explore creative solutions to address the problems 
related to the prosecution of non-controlled NPS.
The first part of this joint report is aimed at policymakers. It lists four challenges in NPS 
control, and then describes the different legislative solutions used in many of the Member 
States. Focusing on the innovative new laws that are designed to address the issue, the 
report gives the reader a breakdown of their key elements: the criteria used to define NPS; 
the systems for listing them; and the penalties for non-compliance.
The second part of the report is aimed at legal practitioners. It outlines the NPS judgment of 
the CJEU and its practical effects on transnational prosecution of NPS cases, and describes 
the responses of some of the Member States most affected by the ruling.
Combining the top-level monitoring activities of the EMCDDA with the operational 
experience of Eurojust in transnational prosecutions, this joint report aims to provide 
succinct but useful information to the key actors in this area.
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In recent years the evolution of the European market for new psychoactive substances 
(NPS) has accelerated to a speed that the public authorities’ established response — 
drug control laws — has struggled to match. Internationally, United Nations conventions 
control drugs in order to protect public health, based on identified risks as assessed by the 
World Health Organization. Countries signing the conventions are required to establish 
criminal penalties to deter and punish unauthorised trade in controlled substances. As it 
is a general principle that criminal law must be certain, the substances subject to such 
penalties must be clearly specified, which means listing them individually, or in some 
cases in tightly defined groups according to their chemical structure. On this basis, when a 
new psychoactive substance is identified, its risk to health should be assessed and then it 
could be included in the list of those controlled under the criminal law. However, with about 
560 NPS being monitored by the EMCDDA in 2015 — more than double the number of 
substances controlled under the United Nations international drug control conventions — 
these established approaches struggle to keep pace (EMCDDA and Europol, 2016).
Member States have responded in a variety of ways to this challenge to drug control 
systems. Several Member States had started to rely on the (EU-harmonised) definition of 
a medicinal product to rapidly control NPS. However, the judgment of the Court of Justice 
of the European Union (CJEU) of 10 July 2014 (known as the NPS judgment) on the 
prosecution of NPS found that they were excluded from the scope of medicinal products 
(CJEU, 2014). Consequently, the prosecution of NPS cases based on medicine laws has 
become more difficult. Additionally, on a transnational level, if the supply of a substance is 
not a criminal offence in the concerned countries (double criminality), judicial cooperation 
becomes very difficult.
Against this background, in September 2014, the outcome report of Eurojust’s Strategic 
Meeting on Drug Trafficking (Eurojust, 2014), held in The Hague on 29-30 September, called 
for a focus on:
‘Exploring “creative” solutions to address the problems related to the prosecution of 
“legal” NPS/pre-precursors, such as the use of administrative laws (e.g. withdrawing 
permits for shops), consumer legislation, and food safety legislation.’  
This Eurojust and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
report therefore presents a joint analysis of the variety of approaches to NPS control 
adopted across the EU and the judicial cooperation challenges related to NPS.
Part I of the report provides a broad overview of the different approaches to NPS control 
adopted across the EU and will be of particular interest to those involved in developing 
legislation and policy in the area.
Part II, which will be of key interest to legal practitioners, focuses on the NPS judgment and 
the effect of this judgment on prosecutions and the current legal framework in Member 
States most likely affected by this ruling, in order to identify and share possible solutions to 
overcome potential obstacles created by the judgment.
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PART I
Legal responses to new psychoactive substances around Europe
Until about 10 years ago, psychoactive substances not listed 
for control within the conventions tended to emerge on the 
illicit drug market. They were limited to a handful of substances 
each year, which were typically passed off as controlled 
drugs such as MDMA (methylenedioxymethamphetamine), 
amphetamine or heroin.
However, over the last decade, entrepreneurs have started 
selling substances not listed for control on the open market, 
reasoning that whatever is not expressly prohibited must 
be allowed for open sale. The combination of globalisation 
and innovation in communications technologies means that 
substances have been developed, produced and marketed 
internationally at great speed, and sold openly in specialised 
shops in towns and cities, as well as via the internet. From this, 
four distinct policy challenges have arisen.
1.  Some substances are so new to the field that, at least 
initially, there is very limited evidence of public health 
risks — the risks being one of the primary justifications for 
punitive control measures.
2.  The process of updating the law can take time; some 
countries require criminal laws to be agreed by 
parliament, which may take more than a year. However, 
the speed with which new drugs appear means that as 
soon as one new psychoactive substance is identified 
by the authorities and controlled a replacement is often 
already on the shelves.
3.  Entrepreneurs have used the lists in the drug laws simply 
as exclusions from their potentially vast product range, yet 
very broad definitions that might control many substances 
can be so vague that a prosecutor has difficulty proving 
that distribution was a crime.
4.  Adding substances to the list obliges law enforcement to test 
for those substances, but technical and financial resources 
for the new tests are not always increased accordingly.
Governments in Europe have responded in different ways 
to the challenges posed by the market in new psychoactive 
substances (NPS). Among these measures designed to 
reduce the availability and use of NPS, three broad, sometimes 
overlapping, groups of legal responses can be identified (1). 
(1)  The EMCDDA receives regular and ad hoc reports and information on drug 
control laws from its national legal correspondents and Reitox networks. 
These sources were used to compile the information presented here on 
the different approaches to NPS control across the EU.
In the first group, existing laws that focused on consumer 
or health protection or medicines have been used. In 
the second group, drug laws have been modified, most 
commonly by introducing group definitions of substances 
under control. In the third group, innovative new laws have 
been developed to address these substances, in a few cases 
even defining a psychoactive substance by its effect rather 
than its chemical structure. 
Consumer safety and medicines laws
A number of European Member States have successfully 
used consumer safety laws, which, as they are based on 
harmonised EU definitions, should already be operational 
(and available for use) in all Member States. In practice, 
different types of consumer safety laws have been 
enforced, some targeting psychoactive products in general 
(as happened in Poland in 2010, resulting in mass closures 
of the specialist sales outlets), others directed towards 
individual substances. In Italy, for example, regulations 
requiring that goods or food on sale be clearly and 
accurately labelled in relation to their expected use have 
been invoked to confiscate products containing synthetic 
cannabinoids that were not labelled in the national 
language. A similar approach was used in the United 
Kingdom to stop the sale of mephedrone labelled as bath 
salts and plant food. Having first used consumer safety 
laws, Poland subsequently modified its legal definition of a 
‘substitute drug’ (a substance used instead of a drug or for 
the same purposes) and updated the health protection law 
so that it could be used when there was suspicion that a 
substitute drug posed a health threat.
As the harmonised EU definition of a medicinal product 
appeared not to require such a product to have beneficial 
effects on human health, there has been room for countries 
to use this legislation to respond to NPS. When a national 
medicines agency classifies a new psychoactive substance 
as a medicinal product, it can then demand a licence for 
any importation, marketing or distribution. In this way at 
least seven Member States (2) have used medicines laws 
to control supply of one or more new drugs at national level 
since 2007. However, in July 2014 the CJEU ruled that 
this was not a correct interpretation of the harmonised EU 
definition, and so this method is now limited; see Part II for 
a full discussion of this NPS judgment.
(2) Germany, Spain, France, the Netherlands, Austria, Finland and the United 
Kingdom.
10
New psychoactive substances in Europe
Modification of drug laws
Another response to the threat of new substances has been 
for Member States to manage them under existing drug 
legislation, through either modification or extension of these 
laws. In order to accelerate legal processes some countries 
have introduced temporary control regimes, allowing time for 
investigation of the need for permanent control. For example, 
temporary control procedures were enacted in Latvia and 
Slovakia in 2013, implemented respectively by the Centre 
for Disease Prevention and Control and the Minister for 
Health. In 2011 the United Kingdom enacted a procedure 
allowing temporary class drug orders, under which named 
substances could be quickly controlled under drug laws for 
up to 1 year. A similar system was enacted in Hungary in 
2012, revising the risk assessment process and allowing the 
addition of non-therapeutic drugs to the list of controlled 
substances on the basis that they can pose as serious a 
threat to public health as substances already listed in the 
drug schedules. In the Czech Republic controlled drugs had 
been listed in a parliamentary law; their transfer to a new 
government decree in 2014 should reduce the time required 
to add new substances in future. At the end of 2014, Finland 
extended its Narcotics Act to cover also ‘psychoactive 
substances banned from the consumer market’, listed 
in a new government decree following the above risk 
assessment, with unauthorised supply punishable by up to a 
year in prison as an offence endangering health and safety.
Several Member States have chosen to extend the coverage 
of existing drug laws by listing tightly defined ‘generic’ 
groups of substances, rather than individual drugs as 
had been done previously. Germany is in the process of 
adopting a group definitions approach and in 2014 Belgium 
established the legal basis to implement it. However, the 
Netherlands rejected it in 2012 because of the complexity of 
targeting some substances while not restricting others that 
may have valid uses.
Innovative legal responses 
A third group of responses are the innovative new laws 
that have been developed specifically to address these 
substances. Three main aspects of the innovative legal 
responses can be identified: the criteria used to define the 
substance or the motivation for use; the listing mechanisms 
that reduce the time needed to control new substances; 
and the levels of punishment established. These are 
summarised below and a country-by-country summary of 
the key elements of the law is provided in the Annex to this 
report. These country summaries include: the wording used 
to legally define a new psychoactive substance; whether any 
criteria of harmfulness is included; the mechanisms used to 
assess and control a new psychoactive substance; whether 
a control measure is temporary or permanent; the agency 
responsible for enforcement; and the penalties possible.
Criteria of psychoactivity, motive and harm
The definition of a substance as requiring control 
usually consists of two of the three following elements: 
a substance should be psychoactive; there should be a 
motive of abuse or intoxication; and there should be some 
possible harm or threat to health (see Table 1).
TABLE 1
Elements considered in innovative legal responses to new psychoactive substances
Defining psychoactive effects Motive (abuse or intoxication) Harm or threat to health
Ireland + Dependence
Latvia (*)
Hungary + +
Austria + + +
Poland + + +
Portugal + +
Romania + Dependence
Slovakia + +
Finland + +
Sweden (*)
United Kingdom (2011) + +
United Kingdom (2016) + +
NB: 
(*)  In the legal responses of Latvia and Sweden there is no mention of the three elements in their laws, as the decision on qualification as a new psychoactive  
substance is taken by a separate entity (see the country summaries in the Annex for more information).
‘+’ indicates that the element is included in the definition. 
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The Irish and Romanian laws set their definition of 
psychoactivity to a certain threshold, with the Irish requiring 
‘significant’ mental disturbance or change (as in Portugal) 
and the Romanian requiring effects comparable to other 
substances controlled as drugs (as in Hungary and 
Portugal). Both also establish the capacity or likelihood of 
causing dependence as a criterion. 
Listing of new psychoactive substances
In an analysis conducted in 2009, the EMCDDA considered 
the implications of the level of administrative decision 
required to list a substance as a drug, with a ministerial 
decree being approved much quicker than a change in 
a parliamentary law, but with a correspondingly lower 
level of scrutiny (Hughes and Blidaru, 2009). In the laws 
considered here ministerial approval is required in Hungary, 
Austria, Poland (for NPS), Portugal and Slovakia; approval 
of the government is required in Finland, and of the 
parliament in the United Kingdom (as the substance will be 
temporarily controlled as a drug); and in Latvia and Sweden 
the decision will be taken by government agencies in the 
health sector (Table 2). The trade-off between the speed 
and supervision of control is important. In Finland the law 
was only passed when the proposal was changed so that 
the decision to control would be taken by the government 
rather than the Ministry of Social Affairs and Health, as it 
was felt that such a fast decision should be accorded due 
oversight. Four Member States have a system in which 
no list of NPS is established, but any substance meeting 
the criteria will be considered to qualify  (Ireland, Poland, 
Romania, United Kingdom) (3). 
TABLE 2
Bodies deciding on inclusion of new psychoactive substances in list
Ministry Government or higher Other No list
Hungary: Human Capacities
Austria: Health
Poland: Health (NPS)
Portugal: Health
Slovakia: Health
Finland: Government
United Kingdom (2011): Home 
Office, approved by parliament
Latvia: Centre for Disease 
Prevention and Control
Sweden: Medical Products 
Agency, National Institute of 
Public Health
Ireland
Poland (‘substances with similar 
effects’)
Romania
United Kingdom (2016)
(3) This approach was also attempted in the Portuguese autonomous region 
of Madeira in 2012, but it was struck down by the Portuguese constitutional 
court for vagueness.
Penalties for offences
The offences defined in the innovative laws relate mainly to 
the supply of NPS (manufacture, import, sale or distribution), 
but some of the laws emphasise advertising the substances 
as a specific offence. The penalties for these offences range 
from simple confiscation and destruction of the product in 
Sweden, to a maximum of 14 years in prison in the United 
Kingdom. The high penalty available in the United Kingdom 
is due to the substance being temporarily considered as 
a controlled drug and thus attracting the same penalty 
as other drug supply offences. The most severe penalties 
available for the different legal measures are listed in Table 
3. In Portugal and Slovakia, only a monetary fine is provided 
for, as the offence is considered administrative rather than 
criminal; this is also the case for manufacture or distribution 
in Poland. Non-criminal penalties may be chosen for 
reasons of proportionality against an uncertain harm, though 
such an approach may complicate judicial cooperation in 
transnational cases, when dual criminality may be required. 
Longer prison sentences are possible in Austria and 
Latvia in the case of serious health consequences, while 
Poland and Romania attach the most severe penalties to 
acts of advertising rather than distribution itself. Only two 
countries have established penalties for possession of NPS 
for personal use, with Hungary criminalising possession 
of preparations that contain more than 10 grams of a new 
psychoactive substance, and Latvia establishing possession 
for personal use as an administrative offence punishable by 
a warning or fine, with possible criminal liability if a further 
offence occurs within a year.
For a more detailed breakdown of the key parts of these 
laws, see Annex.
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TABLE 3
Most severe penalties in legislation for supply of a new psychoactive substance
Imprisonment (years)
Fine in EUR (if no imprisonment)
Confiscation 
(if no fine)Normal Aggravated
Ireland 1 5
Latvia 2 5
Hungary 3 or 5 5 or 8
Austria 2 10
Poland 1 (advertising) — 250 000 (manufacture or distribution)
Portugal — — 45 000
Romania 2 or 3 5
Slovakia — — 332 000
Finland 1 —
Sweden — — — Yes
UK (2011) 0.5 14
UK (2016) 1 7
NB: These are not the only laws that may be applicable to an offence, and in practice penalties will vary with the particular charge chosen in the case.
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PART II
The NPS judgment and its impact on prosecutions
Eurojust surveyed Member States/national desks on 
their NPS legislation and prosecution practices in 2014. 
The results indicated that Germany, Spain, France, the 
Netherlands and Finland were the Member States most 
likely to face challenges as a consequence of the NPS 
judgment (Eurojust, 2015). Therefore, Eurojust conducted 
a second survey after the NPS judgment in 2015, focused 
on these Member States, asking about the challenges they 
face and their specific responses to them.
To begin with, an overview of the NPS judgment is provided 
to demonstrate the complexity and extent of the matter 
at issue. This is followed by consideration of the impact 
of the judgment on those countries that had been using 
medicines legislation to control NPS and how they are 
addressing these issues.
The CJEU judgment on the definition 
of ‘medicinal product’
The case
The NPS judgment arose from a German court’s decision 
whereby the German authorities brought charges against 
the defendants for a breach of the German Medicines Act, 
because at the time the German Act on Narcotic Drugs did 
not cover synthetic cannabinoids. Both defendants were 
convicted of the sale of unsafe medicinal products. On 
appeal, the Federal Court was required to decide whether 
the sale of mixtures containing synthetic cannabinoids 
(used as a marijuana substitute) could induce criminal 
law proceedings on the grounds of unlawful sale of unsafe 
medicinal products. The Federal Court concluded that it 
would depend on whether synthetic cannabinoids could 
be regarded as medicinal products under Article 1(2)(b) of 
Directive 2001/83/EC relating to medicinal products for 
human use (European Parliament and Council, 2001). In 
other words, if the substance did not qualify as a medicinal 
product, no criminal sanctions could be triggered under the 
German Medicines Act.
Against this backdrop the Federal Court requested a 
preliminary ruling on the subject from the CJEU. The 
latter ruled that synthetic cannabinoids are not medicinal 
products since they do not have any beneficial effects — 
either immediately or in the long term — on human health. 
Rather, they are consumed solely to induce a state of 
intoxication and, as such, are detrimental to human health.
The reasoning of the judgment
The CJEU based its decision primarily on Article 1(2)(a) and 
(b) of Directive 2001/83/EC, according to which medicinal 
products are:
‘(a) Any substance or combination of substances 
presented as having properties for treating or 
preventing disease in human beings; or
(b) Any substance or combination of substances which 
may be used in or administered to human beings 
either with a view to restoring, correcting or modifying 
physiological functions by exerting a pharmacological, 
immunological or metabolic action, or to making a 
medical diagnosis.’
The main reasoning of the CJEU may be summarised as 
follows.
nn The wording ‘modifying physiological functions’ does not 
expressly clarify whether the alteration must be positive 
or negative. However, the intent of the legislator clearly 
was — in the view of the CJEU — to include substances 
having a beneficial effect on human beings.
nn The aforementioned intention becomes clearer since 
the terminology ‘modifying’ is employed in connection 
with the wording ‘restoring [and] correcting physiological 
functions’, which implies beneficial effects. 
nn The term ‘modifying’ must therefore be interpreted as 
meaning an alteration accompanied by beneficial effects 
to human health. 
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The effect of the NPS judgment —  
the challenge for prosecution
The decision of the CJEU might give way to legal gaps 
with the potential of undermining NPS prosecutions in 
Member States that resort to medicine law as the legal 
basis for sanctioning the possession, production and/
or trade of NPS. This potential challenge was discussed 
during Eurojust’s Strategic Meeting on Drug Trafficking 
(29 and 30 September 2014), where it was pointed out that 
prosecution was not possible in several Member States 
(Eurojust, 2014). Not being able to prosecute can pose 
serious difficulties to the fight against drug trafficking and 
related cross-border judicial cooperation, as evidenced in 
some of the cases in which Eurojust has been involved (see 
case illustrations on the next page).
Germany, Spain, France, the Netherlands and Finland 
concluded that the NPS judgment created a legal gap in 
their respective domestic systems since medicine laws 
may no longer be used to ground prosecutions in NPS 
cases. However, the extent and nature of the problem 
varied. More specifically, the following points were made.
nn Spain noted that while the qualification of illicit 
substances is grounded on a closed list that does not 
include NPS, prosecution may still be possible under 
Article 359 of the Spanish Criminal Code, a provision 
that criminalises the production, manufacturing or 
marketing of substances that might have an adverse 
effect on human health. This notwithstanding, the 
penalties for this crime type are relatively low, since it 
was not conceived of as covering NPS offences.
nn France explained that, to a significant extent, NPS 
fall outside the scope of the list of narcotics and 
psychotropic substances despite the 2012 legislative 
reform that introduced the generic approach to the 
regulation of NPS (Ministry of Social Affairs and Health, 
2012); that is, criminalisation refers to a group or family 
of products rather than a specific substance. In addition, 
the NPS judgment hindered control actions, especially 
by customs.
nn Finland identified that, after the NPS judgment, if there 
were evidence that a specific NPS could have beneficial 
effects on human health, prosecution could be based on 
medicine law. Accordingly, the Finnish Medicines Agency 
(MFA) issued a statement whereby it acknowledged 
that some NPS could have such an effect. The MFA 
statement is applicable to only a limited number of NPS. 
An additional challenge was that some domestic courts 
interpreted the NPS judgment in a manner that led to 
charges being dismissed despite evidence of beneficial 
effects on human health.  
 
Specifically, the Supreme Court was requested to 
give its decision on how the NPS judgment should be 
interpreted in Finland. There were at least three different 
possible interpretations: (i) that all charges based on the 
old medicine law will be dropped; (ii) that the prosecutor 
has to prove that some NPS also have medicinal effects 
in addition to the intoxicating effects, in which case 
charges could be brought and an accused could be 
convicted; (iii) that the NPS judgment has no direct 
effect on ongoing national proceedings, but it would only 
show the necessity of changing the conflicting national 
legislation accordingly. If there is a conflict between EU 
law and national legislation, it does not mean per se that 
national legislation would not be applicable (YLE, 2015). 
 
The Supreme Court decided that the EU law has priority 
over the national law. If the conflict cannot be avoided 
by interpreting the national law according to the EU 
law, the national law should not be applied. Substances 
that have no beneficial effect on human health and only 
alter the functions of the body cannot be considered as 
medicines. Therefore, such cases cannot be prosecuted 
using the medicine law. The substances have to be 
assessed on a case-by-case basis using the criteria of 
being beneficial or not beneficial for human health.
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In 2013, following several seizures of parcels coming from a 
Dutch company and directed to Italy, the Italian authorities 
uncovered trafficking of NPS. Among the intercepted 
substances (1) was mephedrone (4-methylmethcathinone), 
which is listed in Table I of the Italian Law against 
Psychotropic Substances (Decree 309/90) as being among 
the most dangerous drugs (e.g. heroin, cocaine).
At the beginning of 2014 the case was referred to 
Eurojust to facilitate the execution of letters rogatory to 
gather evidence in the case through judicial measures, 
including search and seizure.
Initially the Dutch authorities agreed on the execution of 
these measures, considering that mephedrone is listed 
in Table I of Dutch drug laws. A parallel investigation 
was also launched against the main suspect, who 
was expected to be arrested in the Netherlands at the 
beginning of 2015.
(1)  Other seized substances were: methylone, 4FA, 4-MEC, pentedrone, 
6APB, MDPV, alpha-PVT, 3-MMC, MMC, isopentedrone, methyltryptamine.
However, the technical analysis of the substances 
seized in Italy appeared to show that the substance 
sent from the Dutch company was not mephedrone but 
a derivative subproduct, thus falling outside the legal 
basis provided in the Netherlands to authorise judicial 
measures. More specifically the Dutch prosecutor 
explained that, following the decision of the CJEU 
in July 2014, the laws on medical products could no 
longer be used to authorise judicial measures against 
the trafficking and production of NPS. The prosecutor 
explored other legislative acts to be applied in this case, 
but concluded that none was viable, thus the judicial 
request from Italy could not be executed due to the 
lack of double criminality and the parallel investigation 
started in the Netherlands had to be closed.
This case illustrates the severe impact that the CJEU 
decision may have on cross-border cooperation on NPS 
in the EU and the difficulties presented by the technical 
analyses of the substances.
In 2014 trafficking of NPS, for example MDPV and alpha-
PVP from China via Spain to Finland, was investigated 
by the Finnish and Spanish national authorities. The 
substances in question were classified in both Member 
States, but on different legal bases: as narcotics in Finland 
and harmful substances for health in Spain. Therefore, 
the trafficking of MDPV and alpha-PVP was a narcotics 
offence in Finland, but not in Spain, where the applicable 
regulation was Article 359 of the Spanish Criminal Code. 
One problem was that 1 kilogram of alpha-PVP was 
analysed in Spain and found to be pyrovalerone, which is 
a narcotics substance in both countries. However, it was 
analysed again in Finland and found to be alpha-PVP.
In June 2014 the case was referred to Eurojust, and the 
first coordination meeting was held in July 2014, just a 
day before the CJEU judgment was given, to agree on a 
way forward in judicial cooperation. It was decided that 
Spain would open a parallel investigation, allowing a 
joint investigation team (JIT) to be established at a later 
stage. Eurojust and Europol would support the JIT. After 
the CJEU judgment was given, it became evident that 
without a JIT it would be difficult to proceed in this case. 
Another coordination meeting at Eurojust was needed to 
find solutions to overcome the legal obstacles. As some 
of the substances destined for Finland were confiscated 
in Spain, and therefore the possession of the substances 
took place in Spain, there was discussion of double 
criminality in court proceedings in Finland. In particular 
there was discussion of whether Finland has jurisdiction 
to investigate the charges of the possession that has 
happened in Spain, if there was no evidence that the 
substance was to be smuggled from Spain to Finland. 
Also, a court decision of the application of Article 359 of 
the Spanish Criminal Code was needed since in Spain the 
harmful substances are not listed.
This case illustrates how international judicial cooperation 
tools, for example JITs, Eurojust coordination meetings 
and the spontaneous exchange of information via Eurojust 
channels, can be crucial in overcoming judicial obstacles 
and legal gaps, such as those created by the NPS judgment. 
In addition, direct contacts in this case were essential, not 
only during the pre-trial investigation, but especially during 
court proceedings, when information on Spanish law and 
legal practice, for example, was needed urgently.
Case illustration I: Mephedrone (4-methylmethcathinone) and subproducts
Case illustration II: 3,4-Methylenedioxypyrovalerone  (MDPV) 
and α-Pyrrolidinovalerophenone  (alpha-PVP)
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Responses to the NPS judgment
Germany, the Netherlands and Finland declared that 
legislative initiatives have been adopted or are being 
planned in response to the judgment, though their nature 
varies. 
nn In Germany, a draft law was adopted by the government 
in May 2016 and the federal parliament in September. 
It is expected to enter into force by the end of 2016. 
Under this draft law, NPS are defined as any substance 
or preparation belonging to the specified generic (group) 
definitions for synthetic cannabinoids and compounds 
derived from 2-phenylethylamine. However, substances 
already listed in the Narcotics Act or Medicines Act 
are excluded. The Ministry of Health can amend these 
definitions in future based on expert advice. The law 
prohibits producing, trading, importing, offering and 
possessing NPS, and empowers the police to confiscate 
and eventually destroy such substances using their 
general powers to protect life and health. Customs 
authorities may confiscate substances that they have 
good reason to believe are relevant NPS. For supply-
related offences the law sets out various penalties, up 
to 10 years in prison for aggravated cases. Trade for 
recognised commercial, industrial or scientific uses is 
excluded.
nn The Netherlands is planning legislative action with 
a view to reconciling legal certainty and clarity with 
the need to avoid being one step behind when the 
chemical composition of substances changes slightly. 
Accordingly, a number of studies have been planned, 
notably: (i) the Dutch Healthcare Inspectorate (IGZ) and 
the Netherlands Forensic Institute are to examine the 
possibility of determining groups of substances that 
can be listed in the Dutch Opium Act; (ii) lawyers are to 
assess the feasibility of resorting to special investigative 
methods and powers under the Commodities Act; (iii) 
additional risk assessment studies taking into account 
health risks in Europe rather than the Netherlands only; 
and (iv) opportunities for temporary listings.
nn Finland replied that, following the NPS judgment, new 
legislation came into force on 20 December 2014. 
Thereby, NPS are covered under the Finnish Narcotics 
Act and listed in the government regulation on the 
consumer market of psychoactive substances. It is 
important to note that for a specific NPS to be forbidden 
in Finland it must be listed in the aforementioned 
regulation. In addition, the Finnish Criminal Code 
was amended so as to provide for a general provision 
of subsidiary application, which criminalises the 
manufacture, import, storage, holding for sale and 
disposal of a prohibited psychoactive substance 
(Chapter 44, Section 5a). This provision will apply only 
where the act is not more severely punished by another 
criminal provision. Therefore, the provision has a limited 
range of application since most NPS offences relate to 
the importing thereof, and consequently are prosecuted 
as smuggling, which provides for a higher criminal 
sanction (Chapter 46, Section 4). Finland stated that 
the legislative reform bestowed greater clarity upon 
the government regulation on the consumer market of 
psychoactive substances. Currently, all substances that 
are enumerated in the annexes to the medicine list can 
be considered medicine without hesitation. Furthermore, 
all NPS are in a single list.
Other countries reacted in other ways. Specifically, the 
following points were noted.
nn Spanish prosecutors endeavour to resort to provisions 
of a more general nature (e.g. offences against public 
health) to avoid impunity.
nn France established a specialised working group within 
MILDECA (4), in the context of the governmental working 
plan on the fight against drugs and abusive behaviour 
2013-2017. The working group was composed of 
representatives of the Ministries of the Interior, Justice, 
Economy and Health, with the mandate of examining 
the legal instruments and/or tools that may be used 
to capture NPS that are potentially dangerous to 
human health. France noted that NPS are submitted 
for regular assessment and classified as narcotics. 
To illustrate this, on 19 May 2015 seven families of 
synthetic cannabinoids were defined as such as per 
the decree of the Minister for Health. Furthermore, 
prosecutors endeavour to balance the existing legal 
gap by indicting, to the extent possible, for criminal 
association (association de malfaiteurs). In addition, if 
the traffickers or distributors present NPS as having the 
same characteristics and producing the same effects 
as illicit drugs, it is possible to resort to the crime of 
incitement to the use or trafficking of drugs (provocation 
à l’usage ou au trafic de produits stupéfiants) under 
the Code of Public Health, Article L.3421-4. This latter 
crime is particularly relevant in respect of online 
commercialisation.
(4) Mission interministérielle de lutte contre les drogues et les conduites 
addictives (Interministerial Mission for the Fight against Drugs and 
Addictive Behaviour). 
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Conclusion
This brief report provides an overview on how different 
European Member States are developing responses to 
a rapidly evolving market for NPS that challenges public 
health, drug policy and the cross-border prosecution of 
drug crimes. Member States are forced to act by the speed 
at which NPS appear and their open sale begins, balancing 
the precautionary principle of rapid control against the 
credibility and enforceability of the criminal law, which is 
not always backed by evidence of harm to public health. 
One response to regulating supply, the classification of 
NPS as medicines, has been curtailed by the CJEU in 
2014. Yet Member States are also using legislation aimed 
at consumer safety or drug control, and even developing 
innovative legislation specifically to address NPS. On a 
transnational level, the prosecution of cases can depend 
on the supply of a substance being a criminal offence in 
both countries. Lessons may be learned from observing 
the evolution of legislation in different Member States 
and seeing how some responses may subsequently 
be adapted. Continuous monitoring of the situation is 
necessary to ensure an effective public health response 
tailored to the needs and context of the particular country.
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Annex
Innovative laws: key elements
This annex provides a country-by-country summary of the key elements of the innovative 
laws, which include: the definition of a new psychoactive substance, noting any criteria 
of psychoactivity, abuse or harmfulness; mechanisms used to assess and control a new 
psychoactive substance; whether a control measure is temporary or permanent; the agency 
responsible for enforcement; and the penalties possible. The countries concerned are: 
Ireland, Latvia, Hungary, Austria, Poland, Portugal, Romania (two laws), Slovakia, Finland, 
Sweden and the United Kingdom (two laws).
The following information is provided in summary form for the purpose of contrasting the general 
approach being used in different EU Member States. The reader should note that much of this 
information is based on translations of original legal texts that have not been certified. 
Ireland
Law: Psychoactive Substances Act 2010
Definition: ‘Psychoactive substance’ means a substance, product, preparation, plant, 
fungus or natural organism that has, when consumed by a person, the capacity to: (a) 
produce stimulation or depression of the central nervous system of the person, resulting 
in hallucinations or a significant disturbance in, or significant change to, motor function, 
thinking, behaviour, perception, awareness or mood; or (b) cause a state of dependence, 
including physical or psychological addiction (Section 1).
Named exclusions: Medicinal products, animal remedies, intoxicating liquor, tobacco 
products, food, controlled drugs, other substances specified by the ministry (Section 2).
Duration of control: Permanent.
Listed by: No list
Offences and penalties: Selling, importing or exporting a psychoactive substance knowing 
or being reckless as to whether that substance is being acquired or supplied for human 
consumption (Section 3). Publishing or displaying an advert to sell substances or to 
promote the consumption of substances for psychoactive effects with information about 
how or where to obtain them (Section 5). On summary conviction, a fine not exceeding 
EUR 5 000 or imprisonment for a term not exceeding 12 months, or both; conviction on 
indictment, a fine or up to 5 years’ imprisonment, or both (Section 20).
Enforcement: Law enforcement
Latvia
Law: Law on procedures for the legal trade of narcotic and psychotropic substances and 
medicinal products (amended 2013), Criminal Code (amended 2014) and Administrative 
Violations Code (amended 2014).
Definition: Substances that are not included in the lists of controlled drugs and for which the 
information has been obtained from the early warning system or from reports received from any 
of five named (forensic) authorities (Law on Procedures (amended 2013), Article 4, part 2).
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Duration of control: Temporary, 1 year.
Listed by: Centre for Disease Prevention and Control.
Offences and penalties: Unauthorised manufacture, acquisition, possession, transportation 
and transfer with the purpose of the distribution of new psychoactive substances or 
products, up to 2 years’ imprisonment, or up to 5 years if the offence has caused grave 
consequences (Criminal Code, Section 2481). Unauthorised acquisition, storage, transport 
or transfer of new psychoactive substances or products containing new psychoactive 
substances, without the intent to sell them, warning or fine of up to EUR 280. Crime if 
repeated within 1 year.
Enforcement: Law enforcement.
Hungary
Law: Government Decree 66/2012, Decree 55/2014, Act XCV on Medicinal Products 2005 
(amended 2015) and Criminal Code (amended 2014).
Definition: A substance that appears on the market (or is formally notified to the EU 
early warning system) will undergo a formalised rapid assessment that must reach two 
conclusions. Firstly, the substance can affect the central nervous system, so it can change 
the mental state, behaviour or perception and therefore pose as serious a threat to public 
health as the substances listed in the 1971 UN convention; and secondly, the substance 
has no therapeutic use (amended Act XCV, Section 15B). May include compound groups.
Duration of control: Temporary, 1 year, renewable. Within 1 year of being placed on the 
‘Schedule of NPS’, the drug must be risk-assessed, resulting in full drug control or transfer 
to the ‘Schedule of substances removed from the Schedule of NPS’. Absence of relevant 
information can extend the risk-assessment procedure by 1 year (or until information 
becomes available with a risk assessment every 2 years). Compound groups will remain 
as long as any substance in the group fulfils the requirements (amended Act XCV 2005, 
Section 15C).
Listed by: Ministry of Human Capacities decree (Decree 55/2014 includes schedule of new 
psychoactive substances) and government decree (Decree 66/2012 includes a schedule of 
substances removed from the schedule of new psychoactive substances).
Offences and penalties: Import, export, transport, manufacture, up to 3 years’ imprisonment 
(if aggravating circumstances, 1 to 5 years). Supplying, placing on the market, offering 
or dealing, 1 to 5 years’ imprisonment (up to 1 year if a small amount, 2 to 8 years with 
aggravating circumstances). Possession for personal use of more than a small amount 
(preparation contains more than 10 grams of new psychoactive substances), up to 3 years 
(Criminal Code Sections 184, 184/A-D). Possession of a small amount is a misdemeanour 
that falls within the competence of the police.
Enforcement: Law enforcement.
Austria
Law: Psychoactive Substances Act 2012.
Definition: Substances not subject to the UN conventions of 1961 and 1971 are listed if 
they have the potential for ‘psychoactive effects’ (stimulating or depressing the central 
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nervous system, resulting in effects such as hallucinations or disturbances in motor 
functions, perception, behaviour, mood) (Section 1(2)), are likely to be used by certain 
sections of society and a threat to consumer health cannot be excluded (Section 3). May 
include compound groups.
Named exclusions: Substances placed on the market in accordance with drug, pharmacy 
or medicine import regulations, as well as substances subject to the Narcotic Drugs Act 
(Section 2).
Duration of control: Permanent.
Listed by: Ministry of Health regulation (Section 3).
Offences and penalties: Unauthorised production, import, export or supply is a crime if the 
supplier aims to benefit and intends that the product be used for its psychoactive effects. 
Punishable by up to 2 years’ imprisonment, or 1 to 10 years if supply results in many 
serious injuries or a death (Section 4). Seizure of any amount of a substance is possible 
even when there is no suspicion of supply (Section 5). Customs may also confiscate 
imported/exported goods (Section 7).
Enforcement: Law enforcement.
Poland
Law: Act amending the Act on Counteracting Drug Addiction and the Act on State Sanitary 
Inspection, 2010; further amended 2015.
Definition: ‘New psychoactive substance’ (NPS) is defined in the 2015 amendment to the 
Act on Counteracting Drug Addiction (ACDA) as a substance of natural or synthetic origin 
in any physical state with effects on the central nervous system that is published in the 
regulation of the Minister for Health. ‘Substitute drug’ is redefined by the amending laws 
as a product containing at least one new psychoactive substance or another substance 
of similar effects on the central nervous system, which might be used instead of, or for 
the same purposes as, a controlled drug, whose manufacture and introduction to trade 
is not governed by separate laws (both definitions in ACDA Article 4). The law makes no 
specific reference to whether the substitute drug should first be considered as harmful; 
NPS are classed as such following risk assessment by a multidisciplinary team. Before the 
2010 amendment, under the Act on State Sanitary Inspection (SSI), the inspectors were 
empowered to act against any ‘failure to meet hygiene and health requirements’. They now 
have the specific right to withdraw from trade a ‘substitute drug’ for up to 18 months in 
order to assess its safety, if there is a justified suspicion that it might pose a threat to life or 
health. If the substance is judged to be potentially harmful, costs are borne by the supplier; 
if not, costs are paid by the state (amended Act on SSI, Article 27c). From 2015 the 
customs office may impound the consignment of imported product if there is reasonable 
suspicion that it might be a substitute drug or new psychoactive substance, for up to 
18 months (amended ACDA, Article 44d).
Named exclusions: Substitute drugs are not governed by regulations on the general safety 
of products (amended ACDA, Article 4).
Duration of control: Substitute drugs, temporary, up to 18 months (amended Act on SSI, 
Article 27c). NPS, permanent.
Listed by: NPS listed by Ministry of Health from 2015; no list of substances ‘of similar effects’.
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Offences and penalties: The penalty for manufacturing NPS or substitute drugs, or 
introducing them into circulation, is a fine by the state sanitary inspector of between  
PLN 20 000 and 1 000 000 (about EUR 5 000-250 000) (amended ACDA, Article 52a). 
The penalty for advertising the psychoactive effects of a substance is up to 1 year’s 
imprisonment (amended ACDA, Article 68).
Enforcement: State sanitary inspector; customs.
Portugal
Law: Decree-law 54/2013.
Definition: Psychoactive substances that pose a public health risk comparable to that 
posed by controlled drugs, from their effects on the central nervous system, with the 
ability to induce significant alterations in the level of motor function, as well as mental 
functions, namely reasoning, critical judgment and behaviour, often with states of delirium, 
hallucinations or extreme euphoria, with the ability to cause dependence and, in certain 
cases, produce long-term or permanent damage to the health of consumers (Article 2).  
Any substance that is suspected of posing a grave risk to human health (Article 7).
Named exclusions: Permission may be given for supply when intended for industrial or 
pharmaceutical purposes (Article 4).
Duration of control: Permanent.
Listed by: Ministry of Health (Article 3).
Offences and penalties: Production, import, export, advertising, possession and distribution 
of these substances or their derivatives (Article 4), closure of the premises involved 
(Article 6), as well as administrative fines of up to EUR 45 000. Users are referred to a 
commission for the dissuasion of drug addiction (Article 10).
Enforcement: Portuguese Economy and Food Safety Authority.
Romania
Law: Joint Ministerial Order establishing mixed teams to control new psychoactive 
substances (2011).
Definition: The order set up multidisciplinary teams of representatives from ministries 
(e.g. health, interior, agriculture) and health and consumer protection agencies, to target 
environments where ‘harmful unregulated psychoactive substances’ were being distributed 
or consumed. The group is tasked to enforce all existing laws in their respective fields to 
stem the distribution of these substances.
Duration of control: Permanent.
Listed by: No list.
Offences and penalties: All relevant existing offences and penalties.
Enforcement: Mixed teams.
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Romania
Law: Law 194/2011 laying down rules to counter operations with products likely to 
generate psychoactive effects, other than provided by current laws.
Definition: Any product (‘substitute’, Article 2a) likely to provoke psychoactive effects 
similar to those caused by substances controlled under drug laws (Article 1). These effects 
are defined as stimulation or inhibition of the central nervous system provoking ‘changes 
in functions and mental processes and behaviour’, or ‘causing dependency’ (Article 2e). 
The law makes no specific reference to ‘harmful’ substances. It establishes a system of 
pre-authorisation via the National Health Veterinary and Food Safety Authority evaluation 
commission. It takes about 5 months for a decision to be made (Articles 3-12).
Duration of control: Permanent.
Listed by: No list.
Offences and penalties (from February 2014): Distribution without a permit (particularly 
if consumption was likely) — 3 months’ to 2 years’ imprisonment when the psychoactive 
effects are unknown but likely, and 6 months’ to 3 years’ imprisonment when the 
psychoactive effects are known (Article 16). Advertising the psychoactive effects —  
1 month’s to 1 year’s imprisonment (Article  19). Distribution of products likely to have 
psychoactive effects without a permit and claiming that they are lawful — 1 to 5 years’ 
imprisonment (Article 17). No penalty for the possession of these substances for the 
purpose of use. Failure to ban access to website within 12 hours — fine of  
EUR 12 000-23 000 (Article 15.1).
Enforcement: Ministry of Health, National Authority for Consumer Protection, National 
Health Veterinary and Food Safety Authority, Ministry of Internal Affairs, Ministry for 
Information Society.
Slovakia
Law: Law 40/2013, amending Act No 139/1998 Coll.; Ministry of Health Decree 298/2013.
Definition: Substances for which there is reasonable suspicion of the existence of 
persistent or sporadic and deliberate abuse, which is accompanied by harmful physical or 
mental reactions (Article 16a(1) of amended Act 139/1998).
Duration of control: Temporary. After 3 years a substance is either deleted from the list or 
is moved to the list of controlled substances following the normal legislative procedure 
(Article 16a).
Listed by: Ministry of Health (Article 16a(4)).
Offences and penalties: Administrative breach of consumer law — selling, promoting 
or putting the life or health of consumers in danger (Act No 128/2002 Coll. on the state 
control of internal market in consumer protection matters, and Act No 250/2007 Coll. on 
consumer protection), maximum fine EUR 332 000.
Enforcement: Slovak Trade Inspection Authority.
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Finland
Law: Narcotics Act (amended 2014), Criminal Code (amended 2014), government decree 
2014.
Definition: ‘Psychoactive substances banned from the consumer market’ means those 
substances used for intoxicating purposes that might be a danger to health and that have 
been decided to be made subject to control in accordance with the decision of the Council 
of the European Union or are positional isomers of such a substance and are neither 
medicines nor narcotic drugs (Section 3). Evaluation by the Finnish Medicines Agency 
together with the National Institute for Welfare and Health, police and customs (Section 3a).
Named exclusions: Medicines and narcotic drugs (Section 3). There are provisions for 
exemptions when the substances may also have industrial or research uses (Section 3b, 
Section 23b).
Duration of control: Permanent.
Listed by: Government decree.
Offences and penalties: Production, import, storage, keeping for sale or transfer is 
punishable by a fine or up to 1 year’s imprisonment (Criminal Code, Chapter 44 (Offences 
endangering health and safety), Section 5a).
Enforcement: Law enforcement.
Sweden
Law: Act of destruction of certain substances of abuse hazardous to health (2011:111).
Definition: The substances covered by the act are goods or substances that: (1) the 
government has decided to list as narcotics or as goods injurious to health; (2) are included 
in an international convention to which Sweden is party but where listing has not entered 
into effect; or (3) can be presumed to be injurious to health (Article 2).
Duration of control: Permanent.
Listed by: Medical Products Agency and Swedish National Institute of Public Health.
Offences and penalties: The only ‘penalty’ is confiscation of property. All matters are 
handled according to the Administrative Act (1986:223) and are not viewed as criminal 
offences. Certain protocols must be used and the decision can be appealed to court.
Enforcement: Law enforcement.
United Kingdom
Law: Police Reform and Social Responsibility Act 2011, amending Misuse of Drugs Act 
1971.
Definition: ‘Temporary class drug orders’ (TCDOs) may be drawn up where a substance is 
misused or likely to be misused, and where that misuse is having, or is capable of having, 
harmful effects (amended Misuse of Drugs Act (MDA), Section 2A(4). To proceed with such 
an order, the home secretary must consult the Advisory Council on the Misuse of Drugs 
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(ACMD). However, there is also an ‘urgency procedure’, to consult only the ACMD chair, 
if the likelihood of misuse poses an urgent or significant threat to public safety or health 
(amended MDA, Section 2B).
Duration of control: Temporary, 1 year (amended MDA, Section 2A(6)).
Listed by: Home Secretary with approval of Parliament (amended MDA, Section 2A).
Offences and penalties: TCDOs apply only to supply-related offences under the MDA 
(amended MDA, Section 2B), and carry the same penalties as drug supply offences, i.e. 14 
years’ imprisonment and an unlimited fine on indictment, or 6 months’ imprisonment and 
a fine of GBP 5 000 (about EUR 6 900) on summary conviction. Simple possession of a 
temporary class drug is not an offence. However, law enforcement officers with suspicion 
may search an individual and seize and dispose of anything they believe is a temporary 
class drug (amended MDA, Section 23A) to prevent possible harm to the individual.
Enforcement: Law enforcement.
United Kingdom
Law: Psychoactive Substances Act 2016.
Definition: A psychoactive substance is any substance that is capable of producing a 
psychoactive effect in a person who consumes it. This means that, by stimulating or 
depressing the person’s central nervous system, it affects the person’s mental functioning 
or emotional state (Section 2).
Named exclusions: Controlled drugs, medicinal products, alcohol, nicotine and tobacco 
products, caffeine and food. Other substances may be added by the secretary of state 
(Section 3, Schedule 1).
Duration of control: Permanent.
Listed by: No list.
Offences and penalties: Producing, supplying or possessing with intent to supply, importing 
or exporting a psychoactive substance with intention, knowledge, or recklessness that the 
substance will be consumed for its psychoactive effects. Supply offences are aggravated 
by proximity to school, using a minor as a courier, or being carried out in a custodial 
institution. Maximum penalties are 7 years’ imprisonment on indictment or 1 year on 
summary conviction. Possession of a psychoactive substance (not for supply) in a custodial 
institution is punishable by up to 2 years’ imprisonment on indictment or 1 year on 
summary conviction (Sections 4-10).
Enforcement: Law enforcement.
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